Jefferies Reiterates Buy on AbbVie (ABBV) After Meeting with Management
- Noble Energy (NBL) to Acquire Clayton Williams Energy (CWEI) for $2.7B in Cash and Stock
- Nasdaq hits record; bank earnings validate Wall St. rally
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
- Time (TIME) Said to Soon Begin Discussions with Interested Buyers - Bloomberg
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies reiterated a Buy rating and $90.00 price target on Abbvie (NYSE: ABBV) after meeting with management. Management expects that the court date for litigation with Amgen should be announced before year end and to expect this to run for at least 3 to 3.5 years before any initial rulings are made. The company is also confident that the business can drive revenue and EPS growth above its peers going forward, driven by strong volume growth for Humira, new product launches and margin expansion.
Analyst Jeffrey Holford commented, "We met with the CEO, CFO and CSO of AbbVie yesterday. Our take is that the next 12 months should see significant visibility emerge on the timeline for Humira biosimilars with the earliest potential US launches being post-2020. Meanwhile the largely de-risked late-stage pipeline continues to gather momentum, giving us increasing confidence that the business can grow through and beyond the eventual introduction of Humira biosimilars."
Shares of Abbvie closed at $63.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Raises Price Target on Abbott (ABT) to $47; Reiterates Buy
- DA Davidson Downgrades Inventure Foods (SNAK) to Neutral, Predicts Company Won't Exist In Current Form Come June 2017
- FBR Capital Raises Price Target on Gentex Corp (GNTX) to $25 Following CES 2017
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!